Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by BioNTech SE

< Previous 1 2 Next >
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Inaugurate First African Site on December 18, 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Completes Acquisition of InstaDeep
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
From BioNTech SE
Via GlobeNewswire
Tickers BNTX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.